CDKN1A and urinary bladder cancer: In an orthotopic bladder cancer mouse model, repeated intravesical administration of p21-LNP significantly suppressed tumor growth, restored p21 expression in bladder tissues, and preserved urothelial architecture without obvious adverse effects.